Using optical imaging to differentiate breast tissue types
Breast Cancer Diagnosis Using Optical Techniques
This study is testing new light-based imaging methods to see if they can safely tell the difference between healthy, benign, and cancerous breast tissues in patients with confirmed tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Region Skane Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Malmö) |
| Trial ID | NCT06857669 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of diffuse reflectance spectroscopy and photoacoustic imaging as non-invasive diagnostic tools for differentiating between healthy, benign, and malignant breast tissues. By analyzing the unique optical profiles of these tissue types, the research aims to provide a safer alternative to traditional diagnostic methods like mammography and biopsies, which can be uncomfortable and expose patients to radiation. The study will focus on patients with biopsy-verified tumors larger than 1 cm, assessing the feasibility of these optical techniques in clinical settings.
Who should consider this trial
Good fit: Ideal candidates for this study are women with solitary biopsy-verified breast tumors larger than 1 cm.
Not a fit: Patients who have undergone previous breast surgery or received neoadjuvant chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to safer, non-invasive diagnostic methods for breast cancer detection and monitoring.
How similar studies have performed: While the use of optical imaging techniques is gaining interest, this specific combination of diffuse reflectance spectroscopy and photoacoustic imaging for breast tissue analysis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * solitary malignant or benign biopsy verified tumour \> 1 cm * understands written and oral Swedish Exclusion Criteria: * previous breast surgery * has received neoadjuvant chemotherapy * skin burns in on the chest
Where this trial is running
Malmö
- Skane University Hospital — Malmö, Sweden (Recruiting)
Study contacts
- Principal investigator: Sophia Zackrisson, MD, PhD — Region Skane, Lund University
- Study coordinator: Sophia Zackrisson, MD, PhD
- Email: sophia.zackrisson@med.lu.se
- Phone: +46 40 33 87 97
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.